BioSpace News Archive

On April 2nd, Berks Heim nursing home employees represented by United Food & Commercial Workers Local 1776 Keystone State overwhelmingly approved a new five-year contract agreement that preserves long-term, quality resident care and ensures long-term job security for hundreds of Berks Heim members who serve the Berks County community.

Provides Flexibility to Execute on Aurora’s Global Expansion and Partnering Strategy

On November 13, 2018, Oregon Endodontic Group became aware of suspicious activity in the office’s email account.

Public schools from Missouri, North Carolina and Virginia have been named grand prize National Winners in the Samsung Solve for Tomorrow Contest

Ethicann Pharmaceuticals Inc., a Toronto based ethical pharmaceutical company using pharmaceutical grade botanically sourced cannabinoid oils to formulate ethical drugs, has closed a successful initial financing round.

EspeRare, a not-for-profit organization dedicated to accelerating the development of rare diseases treatments, today announced that it has entered into an agreement with Dermelix Biotherapeutics for the co-development of its lead programme, DMX-101.

Basel, April 02, 2019 – Novartis, a global leader in immuno-dermatology and rheumatology announced today that the China Health AuthorityNMPA approved Cosentyx® (secukinumab), the first-in-class interleukin-17A (IL-17A) inhibitor for moderate-to severe plaque psoriasis in adultpatients who are candidates for systemic therapy or phototherapy.

Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic presented new data on the KEY-Vaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today presented new data on the Phase 1b study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta, Georgia, USA.

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has completed the acquisition of the US rights to Proleukin® (aldesleukin, human recombinant interleukin-2), following US anti-trust clearance.